Ad campaign for diabetes drug

Takeda Pharmaceutical Company Ltd, the manufacturers of popular type 2 diabetes drug Actos, have announced that they will commence a major advertising campaign throughout America to promote the safety of their drug compared to GlaxoSmithKline’s Avandia.
The news comes at the same time as a forced safety warning on Avandia packaging. Avandia is the greatest rival to Actos, and has recently received a Food and Drug Administration decision that the packaging must carry black-box warnings. Avandia has been confirmed to cause increased risk of heart attack and chest pain.
Sales of Avandia have suffered due to negative press over its risks. Actos, the major rival to the drug, has experienced increased sales as a result. Many doctors and physicians have chosen to switch from Avandia to Actos.
The focus of Takeda adverts will be that the drug does not raise the risk of heart attack or having a stroke.